Physician profile
David K Patzer
NPI 1376780841
$3,598.25
in general payments reported to CMS, 2019-2025
27 companies · $564 in 2025
The $564 reported for 2025 was more than what 77% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.63 · 2020: $21.40 · 2022: $805 · 2023: $1,343 · 2024: $849 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,756.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $650.24 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $424.22 | 2020-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $375.22 | 2022-2025 | |
| Axsome Therapeutics, INC. | $244.55 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $185.06 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $164.81 | 2022-2024 | Austedo Xr, Austedo |
| Ironshore Pharmaceuticals INC. | $153.99 | 2022-2024 | Jornay Pm |
| Corium, LLC | $144.15 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $131.14 | 2022-2025 | Aplenzin |
| Supernus Pharmaceuticals, INC. | $131.09 | 2022-2023 | Qelbree |
| Noven Therapeutics, LLC | $127.61 | 2024-2025 | Xelstrym, Secuado |
| Lundbeck LLC | $106.92 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.54 | 2022-2024 | Caplyta |
| Neos Therapeutics, LP | $97.91 | 2022-2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $86.39 | 2023 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $86.16 | 2022-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $79.43 | 2022-2024 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $73.06 | 2023-2025 | Trintellix |
| Indivior INC. | $63.99 | 2024-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $28.52 | 2022 | |
| Acadia Pharmaceuticals INC | $24.94 | 2025 | Nuplazid |
| Biogen, INC. | $23.86 | 2024 | Zurzuvae |
| Harmony Biosciences LLC | $21.73 | 2024 | |
| Collegium Pharmaceutical, INC. | $21.39 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $17.16 | 2022 | |
| Livanova USA, INC. | $16.54 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Adlon Therapeutics L.P. | $15.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Patzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.